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AbstrAct
The Runx genes function as dominant oncogenes that collaborate potently with 
Myc or loss of p53 to induce lymphoma when over-expressed. Here we examined the 
requirement for basal Runx1 activity for tumor maintenance in the Eµ-Myc model 
of Burkitt’s lymphoma. While normal Runx1fl/fl lymphoid cells permit mono-allelic 
deletion, primary Eµ-Myc lymphomas showed selection for retention of both alleles 
and attempts to enforce deletion in vivo led to compensatory expansion of p53null blasts 
retaining Runx1. Surprisingly, Runx1 could be excised completely from established Eµ-
Myc lymphoma cell lines in vitro without obvious effects on cell phenotype. Established 
lines lacked functional p53, and were sensitive to death induced by introduction of a 
temperature-sensitive p53 (Val135) allele. Transcriptome analysis of Runx1-deleted 
cells revealed a gene signature associated with lymphoid proliferation, survival 
and differentiation, and included strong de-repression of recombination-activating 
(Rag) genes, an observation that was mirrored in a panel of human acute leukemias 
where RUNX1 and RAG1,2 mRNA expression were negatively correlated. Notably, 
despite their continued growth and tumorigenic potential, Runx1null lymphoma cells 
displayed impaired proliferation and markedly increased sensitivity to DNA damage 
and dexamethasone-induced apoptosis, validating Runx1 function as a potential 
therapeutic target in Myc-driven lymphomas regardless of their p53 status.
INtrODUctION
Runx1 encodes a transcription factor that plays a 
vital role in development of the haematopoietic system 
[1]. It belongs to a three-membered family of mammalian 
gene products that bind a common DNA target sequence 
by virtue of the conserved Runt domain and share a 
common heterodimeric binding co-factor, CBFβ [2, 3]. 
Like their Drosophila homologue, Runt, the Runx proteins 
function as transcriptional regulators and are capable of 
activating or repressing target promoters through the 
recruitment of co-activators or co-repressors [4]. The 
RUNX1 (AML1) and CBFB genes are among the most 
commonly involved in human leukemias where they are 
affected by chromosomal translocations that frequently 
generate fusion oncoproteins [5].
Evidence that simple over-expression of any of 
the Runx gene family members can drive oncogenesis 
emerged first from mouse models, where it was shown 
that all three genes can act as targets for murine leukemia 
virus (MLV) insertional mutagenesis and transcriptional 
activation in lymphoma. Common targets in the Eµ-Myc 
lymphoma model include Runx1 and Runx3 [6], while 
all three members of the Runx family were identified as 
activation targets in CD2-MYC T-cell lymphomas [7-
9]. The potent oncogenic effect of combining Myc and 
Runx over-expression is emphasised further in retroviral 
acceleration of lymphoma onset in Runx2 transgenic mice 
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which frequently entails activation of c-Myc or N-Myc 
[10], while compound transgenic mice over-expressing 
Myc and Runx genes in the T or B-cell compartment 
display very rapid tumor onset [10-12]. However, the Runx 
family are not merely cofactors for Myc oncogenesis; 
CD2-Runx2 transgenic mice display dose-dependent 
predisposition to lymphoma [11, 13] and strongly 
synergistic lymphoma development in combination with 
other oncogenes such as Pim-1 and v-Myb, as well as 
with loss of p53 [10]. Notably, the combination of Runx2 
and Myc oncogenes appears to overcome the need for 
mutational inactivation of p53 [14] despite the fact that 
both genes can trigger the p53 pathway and collaborate 
with p53 loss when over-expressed individually [15, 16]. 
In contrast to this catalogue of evidence of dominant 
oncogenic activity in lymphomagenesis, Runx1 deficient 
cells in chimeric mice develop T-cell lymphomas after 
treatment with ENU [17], suggesting that loss of Runx1 
activity can also predispose to lymphoid malignancy. A 
similar dichotomy of observations exists for RUNX1 in 
human haematopoietic cancers. RUNX1 is among the most 
over-expressed genes in childhood ALL [18] and is highly 
amplified in a poor prognostic B-ALL subgroup [19] while 
presumptive loss-of-function RUNX1 mutations have been 
observed in a small proportion of T-ALLs where network 
analysis further implicated RUNX1 as a candidate tumor 
suppressor [20]. More extensive evidence of a tumor 
suppressor role for RUNX1 has come from myeloid 
malignancies where loss of function mutation is frequently 
observed in AML, and underlies familial platelet disorder 
with predisposition to AML [21, 22]. 
While the lymphomagenic effects of Runx over-
expression have been amply demonstrated, the requirement 
for basal gene expression in tumor maintenance is an 
important and potentially far-reaching question that has 
been much less well investigated. In this study we tested 
the effects of ablating the endogenous Runx1 gene in the 
well-characterised Eµ-Myc lymphoma model system [23] 
where ectopic expression of Runx1 is known to drive 
lymphomagenesis [12]. We show that primary Eµ-Myc 
lymphomas have an increased requirement for Runx1, 
while this dependency is reduced, but not eliminated, in 
end-stage p53-deficient lymphoma cell lines. Our findings 
shed light on the paradoxical observation that Runx1 
deficiency can also predispose to lymphoma but more 
importantly validate Runx1 function as a therapeutic target 
in p53 wild-type or mutant lymphomas. 
rEsULts
Addiction to runx1 in primary Eµ-Myc 
lymphoma cells is attenuated in established cell 
lines
Eµ-Myc mice develop lymphomas with highly 
variable onset (average 30 weeks) during which they 
acquire a range of secondary mutations in the Cdkn2a-p53 
pathway [24]. To achieve more homogeneous tumor onset 
and facilitate tracking of p53 loss along with Runx1 
deletion, we crossed these mice to a Trp53+/- background. 
Eµ-Myc/p53+/- mice succumb to B-cell lymphomas within 
a much narrower time window [25]. These mice were 
further crossed to generate Mx1Cre/Runx1fl/fl cohorts in 
which we could examine the ability of lymphoma cells to 
survive deletion of the endogenous Runx1 gene. 
Surprisingly, we found no significant difference 
in the rate of onset of lymphoma in Eµ-Myc/p53+/-/
Runx1fl/fl mice with active Cre recombinase (Figure 1A, 
1B), initially suggesting that Runx1 loss had no effect 
on tumor onset. However, PCR analysis (Figure 1C) 
of tumor-bearing spleens showed that the intact Runx1 
allele was strongly retained in the primary tumors, even 
in pIpC-treated mice. Spleens from mice with end-stage 
disease, which were markedly enlarged due to lymphoma 
expansion, showed levels of Runx1 deletion significantly 
lower than normal splenic lymphoid cells from age-
matched Mx1Cre+/Runx1fl/fl mice without the Eµ-Myc 
oncogene, indicating an increased rather than a decreased 
requirement for Runx1 in primary lymphoma cells (Figure 
1C, upper panel and lower right panel). 
While the cell lines derived from these lymphomas 
almost uniformly retained the functional active Runx1 
allele on initial establishment in culture (Figure 1D, upper 
left panel), they were able to survive excision of both wild-
type alleles after treatment with IFNβ in vitro (Figure 1D, 
upper right panel). Moreover, single cell cloning of these 
lines after low dose IFNβ readily generated subclones with 
0, 1 or 2 intact Runx1 alleles (Figure 1D, lower panel). 
Using these lines we validated the direct PCR assay 
as a consistent measure of the proportion of excised to 
non-excised allele. In this assay, the observed ratio of 
excised to non-excised allele is proportionate to input and 
independent of DNA concentration (Figure S1A, S1B). 
Permissiveness for runx1 deletion is lineage-
dependent
In accord with previous reports [26], analysis of 
non-tumor bearing mice revealed lineage-dependence 
in permissiveness for Runx1 deletion. Healthy tissues 
showed a marked difference in the levels of spontaneous 
and enforced deletion of Runx1, with thymus consistently 
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more resistant than kidney or spleen. However, even the 
permissive tissues showed at most 50% deletion (Figure 
2A). Mono-allelic deletion in Runx1fl/fl cells has been 
reported previously in Runx1-dependent tissues from 
vav-CreRunx1fl/fl mice [26]. These results suggest that a 
strong homeostatic process selects for cells that retain at 
least one copy of Runx1. Consistent with this hypothesis, 
the cell type composition of spleen showed remarkably 
little change after enforced Runx1 deletion (Figure 2B). 
However, fractionation of spleen cells into lymphoid 
(B220+ or CD3+) or myeloid (Mac1+) confirmed the 
relative permissiveness of the myeloid compared to the 
lymphoid compartment for deletion of Runx1 [26] (Figure 
2C). 
Enforced deletion of runx1 promotes the 
outgrowth of p53 null cells in Eµ-Myc/p53+/- 
lymphomas
Established lymphoma cell lines were found to 
have lost the wild-type Trp53 allele in most cases and 
displayed consistent de-repression of Cdkn2a/p19Arf 
[24] (Figure 3A, S2A). We therefore considered whether 
the contrasting behaviour of primary lymphomas and 
established cell lines with regard to retention of Runx1 
was a consequence of loss of the wild-type Trp53 allele. 
To address this hypothesis further and examine the 
temporal order of events in vivo, we analysed the minor 
Figure 1 : Eµ-Myc lymphomas strongly resist deletion of Runx1 in vivo but not in vitro. A. Outline experimental design 
Lymphomas derived from Mx1Cre+/Runx1fl/fl/Eµ−Myc/p53+/- mice were analysed and also used to establish cell lines that could be treated 
in vitro with IFNβ to induce Runx1 excision. b. Survival curve for Runx1fl/fl/Eµ−Myc+/p53+/- mice with or without the Mx1Cre transgene 
and with or without pIpC treatment to excise Runx1. Statistical analysis by Wilcoxon Rank Sum test showed no significant difference in 
survival between the groups of mice. c. Upper panel : Runx1 excision PCR on genomic DNA derived from lymphoma spleen tissue of 
pIpC-treated Mx1Cre+/Runx1fl/fl/Eµ-Myc+/p53+/- mice (lymphoma spleen) and age-matched Eµ-Myc- (lymphoma-free) littermate controls 
(littermate control spleen). Arrows indicate Runx1-floxed (f) and Runx1-deleted (∆) bands. The panel below left shows a diagram of the 
multiplex PCR for detection of deleted (∆) and floxed (f) Runx1. The cartoon shows loxP sites flanking exon 4 in the floxed allele before 
and after excision, location of primers (colored arrows) and size of PCR products. The panel below right shows the ratio of excised:non-
excised band intensity determined by densitometry for the Runx1 excision PCR samples shown in 1C. Boxplot shows the distribution of all 
the ∆:f ratios with the box representing the 1st to 3rd quantiles (Q1 to Q3) and the midline representing the median. Whiskers represent the 
smaller of the most extreme data point, or 1.5x the Q1-Q3 interquantile range. Asterisks denote statistical significance, with p = 0.008 D. 
The upper left panel shows Runx1 excision PCR on genomic DNA from a series of independent cell lines derived from Mx1Cre+/Runx1fl/fl/
Eµ-Myc+/p53+/- lymphomas. The right panel shows Runx1 excision PCR on genomic DNA from samples of 44s and 6s Mx1Cre+/Runx1fl/fl/
Eµ-Myc+/p53+/- cell lines treated with IFNβ to excise Runx1 or with vehicle control; cell samples were taken 2 days after the start of IFNβ 
treatment. The lower panel shows Runx1 excision PCR on genomic DNA from single cell clones derived from the 44s and 6s Mx1Cre+/
Runx1fl/fl/Eµ-Myc+/p53+/- cell lines; cells were treated with a sub-optimal dose of IFNβ to induce partial excision of Runx1 and single cell 
cloned as detailed in Materials and Methods. Arrows indicate Runx1floxed (f) and Runx1-deleted (∆) bands.
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blastic fraction of cells from end-stage lymphoma-bearing 
spleens, a procedure that has been shown to enrich for 
the most rapidly proliferating cells within the tumor 
[27]. The fractionated blasts displayed strong enrichment 
for cells that had lost the wild-type Trp53 allele (Figure 
3B). The fact that most lymphoma blast cells retained at 
least one Runx1 allele indicated that loss of p53 was an 
earlier event that preceded permissiveness for Runx1 loss, 
a conclusion reinforced by findings on newly established 
cell lines (Figure 1D, upper left panel). Enrichment for 
p53-deleted blasts was observed most strongly in pIpC-
treated mice, suggesting that attempts to enforce deletion 
of Runx1 may have perturbed the tissue sufficiently to 
create a permissive niche for outgrowth of bystander p53-
/- blasts. These results further emphasise the importance 
of Runx1 for survival of Eµ-Myc lymphoma cells in vivo, 
even though it becomes dispensable in established cell 
lines in vitro. 
The hypothesis that Runx1 is required to counteract 
the growth suppressive effects of p53 was tested by 
transduction of a p53 null Eµ-Myc/Runx1fl/fl lymphoma 
cell line (3s) with a temperature-sensitive p53 allele 
Figure 2: Healthy tissues display lineage-specific differences in permissiveness for Runx1 deletion. A. Runx1 excision 
PCR analysis of genomic DNA from whole thymus (T), spleen (S) and kidney (K) of non-lymphoma-bearing adult Runx1fl/fl mice treated 
(upper panel) or untreated (lower panel) with pIpC to induce Mx1Cre expression. Arrows indicate Runx1floxed (f) and Runx1-deleted (∆) 
bands. b. Flow cytometric analysis of spleen cell populations in pIpC-treated Mx1Cre- and Mx1Cre+ Eµ-Myc- healthy littermate control 
mice. Plot shows mean ± SD for measurements from 3 mice in each group; no statistically significant differences between the Mx1Cre+ and 
Mx1Cre- cell populations were found. c. Runx1 excision PCR analysis of genomic DNA from sorted lymphoid (B220+ or CD3+ cells; L) 
and myeloid (Mac1+; M) cells from non-lymphoma-bearing spleens of 5 pIpC-treated adult Runx1fl/fl mice. Boxplot shows the distribution 
of all the ∆:f ratios as described in Figure 1. Asterisk indicates that the difference is statistically significant (p = 0.01) . 
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(Val135). After transduction, interferon treatment was 
used to produce matched pairs of cell lines with or without 
endogenous Runx1 that could be tested for sensitivity to 
p53-induced death. However, the p53 “add-back” cells 
died by apoptosis at the permissive temperature (32°C) 
regardless of their Runx1 status or exposure to UV 
irradiation (Figure 3C, 3D, S2B). The functional integrity 
of the p53 pathway was maintained with respect to down-
regulation of Cdkn2a/p19ARF in response to temperature 
shift but the major target for p53-mediated growth arrest, 
Cdkn1a/p21WAF1, was undetectable in these cells (Figure 
3E), suggesting a partial functional deficit. As it has been 
reported that p53 can affect Runx1 expression in T-cells 
[28], we also examined Runx1 expression in 3s cells, but 
saw no evidence of modulation by p53 (Figure 3E).
Runx1 deficient cells display down-regulation of 
genes involved in growth and proliferation along 
with de-repression of Rag genes
Changes in gene expression resulting from 
deletion of Runx1 were examined using Affymetrix 
gene expression microarrays (Affymetrix GeneChip 
MTA 1.0). Three biological replicates of the 3s cell line 
were compared. Possible confounding effects of IFNβ 
treatment and Cre recombinase induction were controlled 
by comparison with a phenotypically matched Eµ-Myc 
lymphoma cell line (30s) of the same genotype apart from 
the non-deletable Runx1wt/wt allele. Treatment with IFNβ 
had no effect on Runx1 expression in these cells (Figure 
S3A, S3B). 
Many genes showed changes in expression specific 
Figure 3: Loss of p53 precedes permissiveness for Runx1 deletion during establishment of lymphoma cell lines. A. Left 
panel: p53 allele PCR on genomic DNA from a series of independent cell lines derived from lymphomas in Mx1Cre+/Runx1fl/fl/Eµ-Myc+/
p53+/- mice; arrows indicate p53null (p53KO) and wild type (p53WT) alleles in control samples for p53wt/wt and p53+/-; asterisks indicate cell 
lines established from pIpC-treated mice. Right panel: western blot analysis of total protein extracted from two established and independent 
lymphoma cell lines derived from lymphomas in Mx1Cre+/Runx1fl/fl/Eµ-Myc+/p53+/- mice that did not receive pIpC treatment. Extracts 
were probed with antibodies to p53, p19ARF and p21WAF1. Actin was used as a loading control. Positive controls are listed in Materials & 
Methods and used in all subsequent analyses. b. Upper panel shows p53 allele PCR on genomic DNA from sorted blast cells  (B) or whole 
tissue (T) from lymphoma-bearing spleens of untreated and pIpC-treated Mx1Cre+/Runx1fl/fl/Eµ-Myc+/p53+/- mice, while the lower panel 
shows Runx1 excision PCR on the same DNA samples. Blast cells were sorted using CD45/SSC on B220+ cells as detailed in Materials 
and Methods. Arrows indicate p53null (p53KO) and wild type (p53WT) alleles, and Runx1floxed (f) and Runx1-deleted (∆) bands. c. Cells 
transduced with vector expressing temperature-sensitive p53V135 or the MigR1 control vector were treated with IFNβ to excise endogenous 
Runx1, and expression of p53 and Runx1 examined by western blot analysis. D. Paired Runx1+ and Runx1null p53 addback cell lines treated 
with 5J/m2 UV were grown at 32°C to activate temperature sensitive p53 and stained for intracellular activated caspase 3 after 3, 4, 6 and 
8h incubation. The percentage of cells expressing activated caspase 3 was determined by flow cytometry. Line colors are indicated by the 
color-coding of the western blots samples in 3C. E. Western blot analysis of total protein extracted from the experiment as shown in (D) 4h 
after UV treatment. Extracts were probed as before and loading confirmed by actin expression. 
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Figure 4: Gene expression microarray analysis of Eµ-Myc lymphoma cells before and after Runx1 excision A. Process 
overview. 3s+ and 30s+ cell lines derived from Mx1Cre+/Runx1fl/fl/Eµ-Myc+/p53+/- mice were treated with IFNβ, excising Runx1 from 
3s cells (Runx1fl/fl) but not 30s controls where interferon responses induce Cre expression but deletion does not occur on the Runx1wt/wt 
background (see also Figure S3). RNA was extracted and gene expression examined by Affymetrix microarray. Significantly changed 
genes were selected by p-value and fold-change and a subset that were also significantly changed in 30s cells were subtracted to exclude 
non-Runx1 related changes. This gene list was then used in downstream analyses such as pathway analysis. b. Heat map of all genes 
significantly changed in 3s cells, defined as p < 0.05 and fold change  >  |1.25|. Shown is raw intensity for 3s and 30s cells. Low expression 
is shown in blue and high expression in yellow. 30s gene expression was normalised to 3s control (-IFNβ) expression. 
Figure 5: Gene expression changes specific for Runx1 deletion in Eµ-Myc lymphoma cells. A. Ingenuity Pathway Analysis 
of the most changed genes (Figure 4) revealed significant enrichment for genes involved in the processes depicted. P-values are shown 
for top sub-processes in relevant categories. b. Venn diagram showing the overlap of the gene signatures for the significant processes in 
A. Genes in bold italics show increased expression on loss of Runx1, while the remainder are down-regulated. c. Validation of key target 
genes contributing to the Runx1 deletion signatures. Fold changes estimated by microarray and RQ-PCR are shown alongside comparable 
array values for the 30s control cells. 
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to the Runx1fl/fl genotype. To focus on the most prominent 
changes we applied a statistical significance threshold 
of p = < 0.05 and a fold change cut-off of 1.25. After 
subtraction of genes significantly changed in the 30s 
control, this left 123 genes of which 70 were up-regulated 
and 53 down-regulated on excision of Runx1 (Figure 
4A). As can be seen from the heat map in Figure 4B, the 
control 30s cells showed relatively modest changes after 
IFNβ treatment compared to Runx1fl/fl 3s cells. The gene 
set specific for Runx1 loss was subjected to Ingenuity 
Pathway Analysis which revealed significant associations 
with cancer and in particular with proliferation, apoptosis 
and differentiation of lymphocytes (Figure 5A). The 
direction of changes on deletion indicated that Runx1 
is acting to sustain proliferation and survival while 
impeding differentiation in these cells (Figure 5B). Rag1 
and Rag2 were common components of all four pathway 
clusters (Figure 5B) and were among the most strongly 
de-repressed genes in Runx1-deleted cells. Validation of 
the changes in Rag genes and other signature genes by 
quantitative real-time PCR confirmed the array findings 
and revealed larger fold changes in most cases, consistent 
with the precision but systematic underestimation of 
differences by this methodology [29] (Figure 5C). 
As recent studies have defined Runx1/RUNX1 gene 
expression signatures in other contexts, we examined our 
array data for similar changes in the key genes. An RNA-
Seq study of normal haematopoietic stem and progenitor 
cells using the same Runx1fl/fl allele revealed a ribosome 
biogenesis gene expression signature associated with loss 
of Runx1 [30]. However, we saw no significant difference 
in these genes. A subset of the most changed genes from 
the signature gene set is shown in Figure S3C. Nor did 
we note any obvious change in cell size or morphology in 
Runx1-excised Eµ-Myc lymphoma cell lines (Figure S3D). 
We also examined a mitotic checkpoint gene signature 
that was reported in Kasumi/AML cells after knockdown 
of RUNX1 [31]. The genes shown in Figure S3E were 
all significantly downregulated in Kasumi knockdown 
cells but were mostly unchanged in Runx1null Eµ-Myc 
lymphoma cells. Only Nek6 was significantly down-
regulated while two of the genes showed a significant 
increase (Nek2, Bub1b). 
Figure 6: RUNX1 mrNA expression is negatively correlated with RAG1 and RAG2 in a large panel of human ALLs. 
Pearson correlation plots of gene expression (probeset intensities) of RUNX1 vs RAG1 or RAG2 in A all ALL subtypes within the MILE 
database (ref [33]) (n = 750), b. all ALL subtypes with the exception of the t(12;21)/ETV6-RUNX1 subset (n = 692), c. the t(12;21) 
translocation only (n = 58). Plots show p-value and r-value.
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Negative correlation of rUNX1 and rAG mrNA 
expression in a human leukemia panel
Aberrant RAG activity has recently been reported as 
a major source of cancer driver mutations in TEL-RUNX1 
t(12;21) B-cell leukemias [32], leading us to consider 
whether there may be a wider role for RUNX1 in RAG 
mis-regulation in human leukemia/lymphomas. Using 
Partek Genomics Suite 6.6 we examined the relationship 
between expression of RUNX1 and RAG1/RAG2 
expression in a panel of acute and chronic leukemias from 
the MILE study (Microarray Innovations in LEukemia), 
a global microarray study comprising gene expression 
analysis of  > 4000 patients [33]. As shown in Figure 
S4, RUNX1 mRNA expression was relatively uniform 
compared to the RAG genes that displayed markedly 
higher expression in ALLs compared to normal tissues 
and myeloid leukemias. Also, expression of RAG1 was 
significantly higher in t(12;21) ALLs than in other ALL 
types (Figure S4). Comparison of the levels of RUNX1 
and the RAG genes within the dataset (n = 750) identified 
significant, negative correlations between RUNX1/RAG1 
and RUNX1/RAG2 (Figure 6). This pattern was evident in 
the total ALL dataset with or without the t(12;21) subset, 
where interpretation is more complex due to the detection 
of TEL-RUNX1 as well as RUNX1 mRNAs by the RUNX1 
Figure 7: Excision of Runx1 impairs proliferation and survival of Eµ-Myc lymphoma cells in vitro. A. Runx1 excision 
PCR analysis of genomic DNA from duplicate samples of Runx1+ (+) and Runx1null (null) cells or of a 1:1 mixture of these cells (M) on day 
0 and after culture for 43 days. Arrows indicate Runx1 floxed (f) and Runx1-deleted (∆) bands. Results shown are from a single experiment 
representative of 3 independent experiments. b. Increased doubling time of Runx1null cells. Runx1+ and Runx1null cells were plated at a 
density of 2x105 cells/ml and cultured for 24h before counting. Doubling time was calculated as described in Materials and Methods. c.-E.
Increased sensitivity of Runx1null cells to chemotherapeutic agents and oxidative stress. Runx1+ and Runx1null were plated at 2x105 cells/ml 
and treated with 1.0µM doxorubicin (C), 0.8% ethanol (D) or 1.0µM dexamethasone (E) for 24-30 hours before viability counting. Plots 
show mean ± SD for a single experiment carried out in triplicate and are representative of at least 3 independent experiments; * = p < 0.05, 
** = p < 0.01.  
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probe sets. While the lack of significant correlation 
between RUNX1 and RAG1 and the weaker correlation 
between RUNX1 and RAG2 in t(12;21) cells is therefore 
difficult to interpret, the strongly negative correlation in 
other ALL sets is a robust observation. 
Eµ-Myc lymphoma cells lacking Runx1 display 
growth impairment and increased sensitivity to 
genotoxic stress and dexamethasone-induced 
apoptosis
Careful observation suggested that the Runx1null cell 
lines grew more slowly, and this suspicion was confirmed 
by serial passage of clonal Eµ-Myc/Runx1fl/fl cell lines in 
which partial excision had been induced. Cells retaining 
Runx1 consistently outgrew their null clonal siblings 
(Figure 7A). This disadvantage could be accounted for 
by the observed lengthening of doubling time in Runx1-
deleted cells (Figure 7B) operating over the prolonged 
culture period. Marked differences were also noted 
when cells were exposed to genotoxic stresses, where 
Runx1null cells displayed more rapid death in the presence 
of doxorubicin or ethanol (Figure 7C, 7D). The effects 
of ethanol were particularly potent on Runx1null cells 
(Figure 7D), possibility reflecting the fact that ethanol 
elicits wider oxidative stress-induced effects in addition 
to DNA damage [34, 35]. In light of our previous findings 
that ectopic Runx1 expression suppresses glucocorticoid 
growth inhibition in murine fibroblasts [36] we also tested 
the effects of dexamethasone. Again, Runx1-deficient 
Eµ-Myc lymphoma cells displayed significantly greater 
induction of cell death (Figure 7E) 
Eµ-Myc lymphoma cells are tumorigenic 
but circulating tumor cells display increased 
sensitivity to dexamethasone
The unexpected survival of Eµ-Myc lymphoma 
cell lines after Runx1 excision in vitro led us to consider 
whether Runx1 is required for lymphoma re-establishment 
in vivo. This was tested by inoculation of NOD-SCID/ 
γCnull (NSG) mice with cell lines with and without excision 
of Runx1 (Figure 8). Retrospective analysis showed 
that the Runx1-excised input cells had a small residual 
fraction of non-excised cells, while the non-excised input 
cells were virtually pure (Figure 8A). Notably, the non-
excised cells appeared to have a significant advantage in 
cells obtained from ascites but not in tumors that arose 
within the skin at the injection site, where mainly excised 
cells were observed. As these mice were not treated 
with pIpC, the non-excised cells had clearly undergone 
spontaneously induced deletion in the skin tumor deposits. 
While this phenomenon may also reflect local production 
of endogenous IFNβ in skin e.g. by plasmacytoid 
dendritic cells [37] the key observation for this study is 
that tumors can develop in vivo with no detectable Runx1. 
This analysis also shows that there is a strong selective 
advantage for retention of Runx1 in cells growing in 
suspension in the peritoneal cavity. 
We also tested the effects of administration of 
dexamethasone on tumor formation. The most striking 
observation here was in circulating cells in blood, where 
dexamethasone treatment had a much greater effect in 
eliminating excised cells compared to their non-excised 
counterparts (Figure 8B). This observation illustrates the 
fact that the growth requirements of cells in vivo cannot 
be fully elucidated in vitro and suggests that free cells 
Figure 8: Runx1null lymphoma cells are tumorigenic but are out-competed by Runx1fl/fl cells in ascitic fluid and in the 
blood of in dexamethasone-treated mice. A. Runx1 excision PCR on genomic DNA from vehicle control (Runx1+) or IFNβ-treated 
(Runx1null) 3s cell line cells (“input”), and from cells from ascites fluid (upper panel) and tumors in skin (lower panel) derived from 4 mice 
transplanted IP with each of the input cell types. b. Runx1 excision PCR on genomic DNA of cells derived from blood and spleen of 12 
mice comprising 6 mice transplanted intravenously with Runx1+(3s+) and 6 with Runx1null (3s-) cells, and 3 mice from each of these groups 
treated with dexamethasone or vehicle control as detailed in Materials and Methods.
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in circulation are most dependent on Runx1 for their 
survival. Notably, some splenic lymphomas appeared to 
consist of exclusively Runx1null cells (Figure 8B, lower 
panel), again indicating attenuation of Runx1-dependency 
compared to primary lymphomas. 
DIscUssION
Previous studies have shown that ectopic expression 
of the Runx genes as a result of retroviral insertional 
mutagenesis or transgenic over-expression is potently 
synergistic with over-expressed Myc or loss of p53 in 
lymphomagenesis [9-11, 38, 39]. The present study shows 
that basal expression of the normal Runx1 gene is vital for 
maintenance of primary Myc-driven lymphoma in vivo and 
that this dependence is stronger than in normal lymphoid 
cells, providing evidence of oncogene addiction in vivo. 
Surprisingly, lymphoma-derived cell lines were able to 
proliferate indefinitely and remained tumorigenic after 
complete excision of Runx1. This is a telling observation, 
as it demonstrates that Runx1 is not merely a structural 
component of the transcriptional apparatus that confers 
B-cell identity and sustains viability. However, Runx1null 
lymphoma cells displayed growth impairment compared 
to Runx1 non-excised controls and were hypersensitive 
to DNA damaging agents and glucocorticoids. On 
transplantation, cells retaining Runx1 also had a selective 
advantage when growing as non-adherent cells in the 
peritoneal cavity and as circulating cells in the blood of 
mice treated with glucocorticoid. These observations 
suggest that Runx1null cells may be partially protected by 
supportive sites of high cell density in vivo. 
The ability of p53null Eµ-Myc lymphoma cell 
lines to survive Runx1 deletion suggested a possible 
functional link whereby Runx1 protects against Myc-
driven induction of p53 and/or downstream responses, and 
becomes superfluous after loss of the intact Tp53 allele 
during in vitro establishment. However, reintroduction of 
a temperature-sensitive p53 expression construct (Val135) 
into cell lines did not discriminate between Runx1 positive 
and negative cells, which succumbed to apoptosis with 
similar kinetics after temperature shift with or without 
irradiation. It is conceivable that another change, 
secondary to Trp53 allele loss, allows the established cells 
to survive without Runx1. This hypothesis is consistent 
with the observation that the Trp53null blast cell fraction 
in vivo showed substantial retention of the intact Runx1 
allele. However, we cannot exclude the possibility 
that ectopic p53 in vitro fails to recapitulate fully the 
behaviour of endogenous p53 in vivo. For example, we 
were surprised to observe a lack of induction of detectable 
CDKN1A/p21Waf1 protein expression in response to 
irradiation and p53 activation. This observation implies 
that established Eµ-Myc lymphoma cells may have lost 
the capacity to undergo cell cycle arrest in response to p53 
induction and choose cell death as the default pathway. 
This phenomenon could account for the increased 
selection against wild-type p53 in cultured lymphoma 
cells compared to their in vivo counterparts [14]. 
The cell-type specific regulatory processes 
controlled by the Runx transcription factors are underlined 
by transcriptome analysis of Eµ-Myc lymphoma cells 
before and after Runx1 excision, which revealed many 
changes that were not evident in control Runx1wt/wt 
lymphoma cells with inducible Cre expression. The 
Runx1 gene expression signature we observed in Eµ-Myc 
lymphoma cells was significantly enriched for regulators 
of lymphocyte proliferation, survival and differentiation, 
with changes consistent with the observed growth 
advantage and chemo-resistance associated with intact 
Runx1 expression. 
The marked up-regulation of Rag1 and Rag2 after 
Runx1 deletion is of particular interest. These genes 
are regulated in a complex, lineage-specific manner in 
T- and B-cells and undergo waves of expression during 
B-lymphocyte development [40]. The promoters of both 
genes harbour multiple Runx binding sites, while further 
Runx motifs are essential for the function of an intergenic 
Rag silencer in T-cells which is over-ridden in double 
positive thymocytes by an anti-silencer upstream of Rag2 
[41]. We also noted strong inverse correlations between 
RUNX1 and RAG1/RAG2 mRNA expression in a panel 
of human leukemias and lymphomas. This is interesting 
in light of evidence that driver mutations are frequently 
induced by aberrant RAG activity in t(12;21) TEL-
RUNX1 leukemias [42] which express unusually high 
levels of RAG1, but also in other genotypes that have no 
known lesion in RUNX1 [43, 44]. The weaker correlation 
between RUNX1 and RAG expression in t(12;21) 
leukemias may be an artefact of the detection of mRNA 
for both TEL-RUNX1 and the untranslocated RUNX1 
allele but may also be a function of direct interference with 
RAG repression by the fusion oncoprotein. Moreover, the 
increased incidence of T-cell lymphomas in ENU-treated 
chimeric mice [17] and the occurrence of apparent loss-
of-function RUNX1 mutations in a subset of ALLs [20] 
might be explained at least in part by dysregulation of 
recombinase gene expression.
We noted very little overlap with changes associated 
with Runx1 deficiency in murine haematopoietic precursor 
cells where ribosomal biogenesis was implicated recently 
as a Runx1-directed function [45]. Apart from their 
separation in the differentiation hierarchy, Eµ-Myc 
cells differ from HPSCs in over-expression of Myc, a 
known driver of ribosome biogenesis [46]. It is therefore 
conceivable that the effect of Runx1 deletion on ribosomal 
gene expression in HSPCs is mediated indirectly through 
loss of signalling to Myc. We also noted diametrically 
opposite effects of Runx1 deficiency on responses to DNA 
damage, where HSPCs were reported to display increased 
resistance [47], while we noted increased sensitivity of 
Runx1null Eµ-Myc cells. While this difference might be 
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related to cell transformation, the relative permissiveness 
to Runx1 deletion of the myeloid compartment in normal 
spleen suggests that lineage-specific factors are likely to 
be involved. Moreover, the increased fragility of Myc-
driven lymphoma cells lacking Runx1 indicates that 
targeting of Runx pathways is likely to be of therapeutic 
benefit in the context of Myc-driven lymphoma. We also 
noted little overlap with the mitotic checkpoint signature 
observed after knockdown of RUNX1 in Kasumi t(8;21) 
AML cells [31]. While lineage-specific differences may 
again be invoked to explain this discrepancy, the AML 
cells also express the RUNX1-ETO fusion protein which 
is likely to modulate at least some of the key promoters 
and enhancers vacated by RUNX1 knockdown.
The finding that basal Runx1 activity is critical 
for Myc-driven lymphoma maintenance in vivo and that 
dependence is only partially attenuated in established 
cell lines lacking p53 is encouraging for ongoing efforts 
to target the Runx genes and their downstream effectors 
in cancer therapy [48, 49]. Moreover, the increased 
sensitivity of Runx1-deleted cells to components of 
standard chemotherapeutic regimens in current use for 
lymphoma therapy suggests that these may be combined 
with Runx inhibition for greater efficacy.
MAtErIALs AND MEtHODs
Generation of transgenic crosses and animal 
experiments
Mx1Cre+/Runx1fl/fl mice [26] were crossed with Eµ-
Myc mice and p53-/- mice to produce highly tumour-prone 
Mx1Cre+/Runx1fl/fl/Eµ-Myc+/p53+/- mice and littermate 
controls lacking Mx1Cre and/or Eµ-Myc. Litters were 
treated at two weeks of age with 8.5mg/kg pIpC injected 
intraperitoneally (IP; two injections two days apart) or 
left untreated; animals were humanely culled when they 
showed signs of tumour development. Runx1wt controls 
(Mx1Cre+/ Runx1wt/wt/Eµ-Myc+/p53+/-) were treated in 
the same way. Adult Eµ-Myc-/Runx1fl/fl mice were treated 
with 6 injections of 600µg pIpC 2-3 days apart at 5 weeks 
of age. Transplantation assays were performed in NOD/
SCID/γCnnull (NSG) mice, which were transplanted IP 
or intravenously (IV) with 5 x 106 Runx1+ or Runx1null 
cells; IV-transplanted mice were treated with 20mg/
kg Dexadresone® IP or vehicle control daily, Monday-
Friday for 3 weeks and 5-10µl blood for flow cytometric 
analysis of B220+ cell counts were removed weekly by 
tail-tipping. Animal protocols used in this work were 
evaluated and approved by the University of Glasgow 
Ethics and Welfare Committee and were carried out under 
Home Office License (approval granted September 2012, 
license number PPL 60/4408) as governed by the Animal 
Scientific Procedures Act, 1986.
statistical analysis
Survival curves were compared using the Wilcoxon 
rank sum test. All other statistical comparisons were 
performed using the Student’s t-test.
Flow cytometry and cell sorting
Phenotyping of spleen cells was performed using 
the following antibodies: anti-B220-phycoerythrin, 
anti-CD4-phycoerythrin, anti-Mac1-PerCPCy5.5 (all 
BD Biosciences) and anti-CD8-FITC (Serotec). Spleen 
cell suspensions in PBS + 0.1% BSA (wash buffer) 
were stained with combinations of antibodies or isotype 
controls for 30 minutes at 4°C, red cells were lysed using 
Pharmlyse (BD Biosciences) and cells were analysed 
using an Accuri C6 flow cytometer and Cflow Sampler 
software (BD Biosciences). Analysis of activated caspase 
3 expression was performed by flow cytometry using the 
PE Active Caspase 3 Apoptosis Kit (BD Biosciences) 
according to manufacturer’s instructions. Sorting of 
spleen lymphoid and myeloid cells was performed using 
a combination of anti-B220-phycoerythrin and anti-CD3-
phycoerythrin to identify lymphoid cells and anti-Mac1-
PerCPCy5.5 to identify myeloid cells. Sorting of blast 
cells from primary lymphomas was performed by staining 
cells with anti-B220-phycoerythin and anti-CD45-FITC; 
in the B220+ population, blast cells were identified using 
CD45 and SSC as reported in [27]. All sorting was 
performed using a FACSAria (BD Biosciences).
Genomic DNA extraction and Pcr
Genomic DNA was extracted from cell lines using 
the DNeasy kit (Qiagen) and from tissues using the 
illustra Nucleon BACC2 DNA extraction kit (GE Life 
Sciences). Determination of DNA concentration was 
carried out using a Nanodrop 2000 (Thermo Scientific, 
Walatham, MA. USA). Analysis of Runx1 excision in 
primary cells/tissues and cell lines was carried out using 
previously described primers and cycling conditions [50]; 
master mix was prepared with 2x ReddyMix, 1.6µM 
each primer and 10ng template DNA. Validation of this 
assay for quantitative determination of Runx1 excision 
was performed by analysing excision in standards 
containing mixtures of 0-100% excised cells. PCR for 
p53 wild-type and null alleles was performed using 
20ng template DNA, 2x ReddyMix (ThermoFisher 
Scientific) and primers directed against p53 intron 
4 (WP53: GTGTTTCATTAGTTCCCCAC), exon 5 
(UP3: ATGGTGGGGGCAGCGTCTCA), and the null 
allele (NP5: CGGTCTTGTCGATCAGGATG); cycling 
conditions were 5 minutes at 94°C, 35 cycles of 1 minute 
at 94°C, 1 minute at 55°C and 1 minute at 72°C, then 7 
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minutes at 72°C, generating PCR products of 242bp (p53 
wt allele) or 470bp (p53 null allele). All PCR products 
were separated on a 1.5 or 2% agarose gel and visualised 
with ethidium bromide and UV transillumination. 
Densitometry was carried out using ImageJ software 
(http://imagej.nih.gov/ij/); images shown were adusted 
only for contrast.
cell culture, constructs and retroviral 
transductions
The 3s, 6s and 44s cell lines were established from 
spleen tissue from primary lymphomas in Mx1Cre+/
Runx1fl/fl/Eµ-Myc/p53+/- transgenic mice and grown in 
RPMI 1640 supplemented with 10% FCS, 100U/ml 
penicillin and streptomycin, 2mM L-glutamine and 50µM 
2-mercaptoethanol (complete RPMI; all reagents from 
Life Technologies). Paired Runx1null and Runx1+ cells 
were created from Runx1fl/fl parental cell lines by treatment 
with 5-50U/ml IFNβ (R&D Systems) or vehicle control 
(PBS+0.1% BSA); Runx1 excision in IFNβ-treated lines 
was confirmed by Runx1 excision PCR. The p53V135-GFP 
was constructed by ligating the 1.4kb EcoR1 fragment 
containing murine p53V135 [51] into the Mig-R1 vector 
[52]. Viral supernatants were prepared following transient 
transfection of GP86+E or 293T cells respectively and 
used to infect 3s cells as described previously [53]. 
Infected cells were sorted for GFP+ cells. Doubling time 
assays were performed in 12-well cell culture plates with 
2x105cells/ml and counted 24 hours after initiation of 
culture; doubling times were calculated using the formula 
Td = ti x (log(2)/log(q2-q1)) where Td = doubling time, ti = 
incubation time, q1 = number of cells at start of assay and 
q
2
 = number of cells at end of assay. Competition assays 
were performed by mixing equal numbers of excised 
and non-excised cells; cells were cultured in duplicate in 
complete RPMI, passaging three times per week, returning 
105 cells to 10ml culture at each passage; Runx1 excision 
in the culture was monitored weekly by Runx1 excision 
PCR. Ethanol, doxorubicin (Stratech Scientific #S1208 
10mM in DMSO) or dexamethasone (Sigma D2915) 
treatment of pairs of excised and non-excised cell lines 
was carried out in 12-well plates using 2x105 cells/ml 
and with the addition of ethanol (0.8%), doxorubicin 
(1.0µM) or dexamethasone (1.0µM). Single cell cloning 
of cell lines was performed by partially excising Runx1 by 
sub-optimal IFNβ treatment and sorting single cells into 
96-well plates in complete RPMI; growing clones were 
transferred to larger culture dishes until sufficient cells to 
analyse were obtained.
rNA extraction and microarray analysis
Total RNA was isolated by RNeasy kit (Qiagen, 
Manchester, UK) from three cultures each of established 
lymphoma lines 3s (Mx1Cre+/Runx1fl/fl/Eµ-Myc+/p53+/-) 
and 30s (Mx1Cre+/Runx1wt/wt/Eµ-Myc+/p53+/-), treated 
with and without IFNβ to excise endogenous Runx1 
(Figure 4A). RNA was tested for quality on the Agilent 
2100 Bioanalyser (Agilent Technologies, Stockport, UK) 
and NanoDrop 2000 (Thermo Scientific, Walatham, MA. 
USA) before screening against Affymetrix GeneChip 
Mouse Transcriptome Array 1.0 (High Wycombe, UK, 
2014) by ATLAS Biolabs (Berlin, Germany) according to 
standard protocols. RMA normalisation followed by probe 
annotation and statistical analysis to generate p-values 
and fold changes was performed using Partek Genomics 
Suite 6.6 (Partek Inc., St.Louis, MO, USA). Microarray 
data are available at the Gene Expression Omnibus (GEO) 
repository, accession number GSE78001. 
Quantitative real-time Pcr
cDNA was prepared from 1µg aliquots of RNA 
using a Quantitect Reverse Transcription kit (Qiagen) and 
diluted 1 in 20 in DEPC-treated water to give a working 
stock. For quantitative real-time PCR, 12.5ng aliquots of 
cDNA were amplified in triplicate on an ABI 7500 real-
time PCR system using Power SYBR Green PCR master 
Mix (Thermo Fisher Scientific, UK), and primers for 
murine Bcl11a, Cd55, Daf2, Il7r, Nckap1, Ptpn22, Prkcb, 
Rag1, Rag2 or endogenous control 18S rRNA (Qiagen 
QuantiTect Primer Assays). Relative quantification was 
carried out and calibrated to vector control samples 
where appropriate. Data were analysed using the standard 
software for the ABI 7500 real-time PCR system. 
Western blotting and antibodies
Preparation of whole cell protein extracts was 
performed as described previously [54]. Samples 
equivalent to 50μg of protein (Bio-Rad protein assay) 
were resolved on 8-12% SDS polyacrylamide gels and 
transferred to enhanced chemiluminescence (ECL; Fischer 
Scientific), nitrocellulose membranes. The antibodies 
used were α Runx1 (#8229 New England Biolabs), α 
p53(FL393), α p21WAF1, α Actin (sc-6243, sc-471 and 
sc-1616, Santa Cruz Biotechnology) and α CDKN2A/
p19ARF (ab80, Abcam). Positive controls were as follows: 
Runx1 (NIH3T3 transduced with pBabeRunx1 P1 [15], 
p53 and p21WAF1 (UVC-treated wild type MEF extract), 
p19ARF (SV3T3 cell extract). 
cONcLUsIONs
Primary lymphoma cells from Eµ-Myc mice show 
evidence of addiction to Runx1 in vivo, but become 
permissive for deletion in vitro. Loss of p53 function 
appears to be necessary but not sufficient for this 
process. In this context Runx1 controls a network of 
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genes involved in lymphocyte proliferation, survival and 
differentiation, shedding light on its dualistic behaviour 
in lymphomagenesis. While the ability of Myc-driven 
lymphoma cells to grow in the absence of Runx1 is 
surprising, their impaired proliferation and increased 
chemo-sensitivity validates Runx1 function as a candidate 
target in future combination therapies.
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